TISLELIZUMAB for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 90 adverse event reports in the FDA FAERS database where TISLELIZUMAB was used for Neoplasm malignant.
Most Reported Side Effects for TISLELIZUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Myelosuppression | 2,142 | 42.9% | 5 | 1,052 |
| White blood cell count decreased | 327 | 6.6% | 5 | 151 |
| Neutrophil count decreased | 277 | 5.5% | 4 | 112 |
| Hepatic function abnormal | 221 | 4.4% | 1 | 144 |
| Pruritus | 213 | 4.3% | 1 | 101 |
| Rash | 208 | 4.2% | 3 | 89 |
| Platelet count decreased | 183 | 3.7% | 10 | 101 |
| Pyrexia | 175 | 3.5% | 3 | 117 |
| Nausea | 165 | 3.3% | 5 | 72 |
| Diarrhoea | 145 | 2.9% | 6 | 87 |
| Liver injury | 139 | 2.8% | 2 | 76 |
| Decreased appetite | 133 | 2.7% | 3 | 72 |
| Off label use | 130 | 2.6% | 11 | 51 |
| Asthenia | 125 | 2.5% | 0 | 73 |
| Anaemia | 119 | 2.4% | 4 | 33 |
Other Indications for TISLELIZUMAB
Lung neoplasm malignant (1,119)
Oesophageal carcinoma (420)
Hepatic cancer (315)
Gastric cancer (264)
Squamous cell carcinoma of lung (246)
Nasopharyngeal cancer (230)
Lung adenocarcinoma (165)
Hepatocellular carcinoma (131)
Metastases to lymph nodes (103)
Adenocarcinoma gastric (99)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)